(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 2. SNAKA51 promotes ligand-binding to
5ß1 integrin, and SNAKA51 binding to
5ß1 integrin is increased in the presence of ligand. Using a solid-phase ligand-binding assay, the binding of biotinylated FnIII (6-10) (0.1 µg/ml) to
5ß1 integrin was measured. (a) Binding of FnIII (6-10) to directly coated placental
5ß1 integrin and to anti-Fc, captured recombinant integrin in the presence and absence of SNAKA51, 12G10, or K20. Statistical analysis was performed using a 2-tailed t-test in comparison to the control without antibody. * P<0.005, **P<0.0005. (b) Dose-dependent binding of biotinylated SNAKA51 to K20 tethered placental
5ß1 integrin in the presence or absence of FnIII (6-10) (20 µg/ml).